Home > Press > Starpharma's DNT Priostar(TM) Dendrimers Significantly Improve Properties of Marketed Fluorescent Reagents
Starpharma (ASX:SPL, OTCQX: SPHRY), through its US subsidiary company Dendritic
Nanotechnologies Inc (DNT), has found that DNT's Priostar(TM) dendrimer
technology can be used to amplify the signal and increase the duration of
the signal (photostability) of existing products in the multi-billion
dollar fluorescent reagents market. The company has filed a patent for the
discovery through DNT.
Starpharma's DNT Priostar(TM) Dendrimers Significantly Improve Properties of Marketed Fluorescent Reagents
MELBOURNE, Australia | Posted on May 7th, 2007
Fluorescent reagents are used extensively in laboratories for high-
throughput screening, diagnostic immunoassays, microarrays, fluorescence
microscopy, genomics and proteomics. Strong signals and photostability are
extremely important properties as they increase the sensitivity of
detection methods and facilitate measurement of the signal, respectively.
Increased sensitivity is needed to study disease markers that are
present at very low levels -- often below those detectable with current
Using its Priostar(TM) technology, DNT has created dye-dendrimer
complexes from various commercial dyes that show significantly enhanced
fluorescent (greater than 10 fold) and photostability (greater than 4
fold), in addition to improved solubility in water.
Preliminary testing has shown that the enhanced properties of
Priostar(TM) dendrimer-dye complexes are retained after attachment to an
antibody, an integral component for many of the applications of fluorescent
"Market feedback indicates that the scientific community and industry
users of these products will highly value the availability of reagents with
increased sensitivity and photostability," said Dr. Lori Reyna, director of
life sciences at DNT. Scientists are always keen to increase the
sensitivity of detection and quantitation methods."
DNT will partner with established leaders in the diagnostic and
research reagent industries through licensing and supply agreements. The
initial commercialization target will be the research reagent and in vitro
diagnostic markets. DNT is currently in preliminary commercialization
discussions with the market leaders in the area of fluorescence reagents.
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in
the development of dendrimer nanotechnology for pharmaceutical,
life-science and other applications. SPL is principally composed of two
operating companies, Starpharma Pty Ltd in Melbourne, Australia and
Dendritic Nanotechnologies, Inc in Michigan, USA.
For more information, please click here
Tel: +61 2 9237 2800
Mob: +61 417 382 391
Dr Jackie Fairley
Chief Executive Officer Starpharma Holdings Ltd
+61 3 8532 2704
Dr Robert Berry
Starpharma Holdings Ltd
+61 3 8532 2702
Copyright © PR Newswire Association LLC.
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Non-Toxic Nanocatalysts Open New Window for Significant Decrease in Reaction Process October 19th, 2014
European Commission opens the gate towards the implementation of Nanomedicine Translation Hub October 16th, 2014
Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014
Tuning light to kill deep cancer tumors: Nanoparticles developed at UMass Medical School advance potential clinical application for photodynamic therapy October 15th, 2014
Physicists build reversible laser tractor beam October 20th, 2014
Removal of Limitations of Composites at Superheat Temperatures October 20th, 2014
1980s aircraft helps quantum technology take flight October 20th, 2014
Ucore's McKenzie to Deliver Presentation to Rare Earths Conference in Singapore as Highlight of Fall 2014 Marketplace Schedule October 19th, 2014
Scientists Map Key Moment in Assembly of DNA-Splitting Molecular Machine: Crucial steps and surprising structures revealed in the genesis of the enzyme that divides the DNA double helix during cell replication October 15th, 2014
DNA nano-foundries cast custom-shaped metal nanoparticles: DNA's programmable assembly is leveraged to form precise 3D nanomaterials for disease detection, environmental testing, electronics and beyond October 10th, 2014
Charged graphene gives DNA a stage to perform molecular gymnastics October 9th, 2014
Nanoparticles get a magnetic handle: New method produces particles that can glow with color-coded light and be manipulated with magnets October 9th, 2014